Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

TimiCoin/TimiHealth Empowers Consumers to Retake Control of Their Genetic DNA Data

Timicoin/TimiHealth, the first operating blockchain designed to empower every individual through the TimiDNA platform allows you to own, control, and monetize your genetic DNA data.

TimiHealth has developed the intellectual property that will protect individuals as they upload their data to the decentralized platform delivering on its trademark branding as the leader in “Tokenized Healthcare™.”

There is no doubt that concerns about health care data– particularly its security and privacy—have been escalating in recent years, said Will Lowe, founder and Managing Partner, Timicoin/TimiHealth.

Read More: Interview with Akemi Tsunagawa, Founder and CEO, Bespoke Inc

The recent announcement that GlaxoSmithKline (GSK) is investing $300M in 23andMe to partner on leveraging genetic DNA data for pharmaceutical drug development with a 50/50 split on future profits further highlights the need for consumer ownership of their own data (https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines/).

While we all support the development of beneficial, perhaps even disease-curing drugs, the subterfuge surrounding the use of people’s personal health and genetic data is deeply concerning, said Lowe.

Related Posts
1 of 40,380

Read More: The Promise and Potential of AI for the Insurance Industry

Millions of people pay companies like 23andMe, Ancestry.com, and Helix substantial fees to obtain information regarding their heritage, genetic disposition for certain disease states, or pharmacologic compatibility with drug regimens.  Unfortunately, most consumers are unaware that the personal data gleaned from such tests can then be sold to any number of research organizations for huge profits—none of which are realized by the consumers themselves.

“TimiHealth and its TimiDNA platform is driven by a mission to remedy these inequities by enabling consumers to own, control, and secure the totality of their health data, including that about their genetic DNA. TimiHealth is built on the principles of trust, transparency and empowerment, with a goal of putting control back into the hands of the true owners of this valuable data—consumers themselves,” said Lowe.

Read More: æternity Partners with Papers.ch to Implement Super-Secure Cold-Signing and Instant Micro-payment Solutions

TimiHealth’s blockchain technology secures health data in an ecosystem that allows individuals to see who wants to purchase their data, to determine whether or not that data is shared and/or sold, and to actually profit from sharing their information by tokenizing and monetizing said data.

TimiHealth encourages all individuals to take immediate control of their data with an option to earn the majority of the profits from the sale of the data.

Read More: Interview with Akemi Tsunagawa, Founder and CEO, Bespoke Inc

1 Comment
  1. Copper scrap refining says

    Copper scrap industry insights Copper scrap sustainability initiatives Industrial scrap metal recycling
    Copper cable shearing, Efficient metal handling, Copper scrap volume forecasting

Leave A Reply

Your email address will not be published.